Voluntary recalls of popular heartburn medication Zantac are expected to be announced on Monday over cancer fears, the TGA said, after traces of a known carcinogen were found in some products. Preliminary testing by the Therapeutic Goods Administration found 40 ranitidine products (the active ingredient in Zantac) out of 44 tested positive for the carcinogen N-nitrosodimethylamine (NDMA). The TGA said the results were "of concern", and that widespread recalls are "quite possible". It wrote to all 11 Australian suppliers and manufacturers of raniditine products last week, requesting urgent information about their batches of products currently in the market. "Several major suppliers are expected to announce voluntary recall actions before COB Monday," a TGA spokesperson told 10 daily. "These recalls plus the one already in progress by Sandoz Australia will now cover the vast majority of stock in the market." 10 daily has contacted Aspen Pharmacare Australia, Zantac Australia’s parent […]